Hospital de Cruces-ko ikertzaileekin lankidetzan egindako argitalpenak (19)

2024

  1. Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

    Blood Cancer Journal, Vol. 14, Núm. 1

2023

  1. Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion

    Cancer Medicine, Vol. 12, Núm. 16, pp. 16788-16792

2022

  1. TP53 Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype

    Cancers, Vol. 14, Núm. 15

2021

  1. Engraftment after autologous hematopoietic stem cell transplantation in patients mobilized with Plerixafor: A retrospective, multicenter study of a large series of patients

    Transfusion and Apheresis Science, Vol. 60, Núm. 3

  2. Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

    Blood Cancer Journal, Vol. 11, Núm. 12

  3. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations

    British Journal of Haematology, Vol. 194, Núm. 4, pp. 708-717

2020

  1. Plzf-rarα, npm1-rarα, and other acute promyelocytic leukemia variants: The pethema registry experience and systematic literature review

    Cancers, Vol. 12, Núm. 5

2017

  1. Monosomal karyotype in chronic lymphocytic leukemia: Association with clinical and biological features and potential prognostic significance

    American Journal of Hematology

  2. Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions

    Oncotarget, Vol. 8, Núm. 33, pp. 54297-54303

2015

  1. Fluorescence in situ hybridization analysis does not increase detection rate for trisomy 8 in chronic myelomonocytic leukemia

    Leukemia and Lymphoma

2014

  1. Interstitial 13q14 deletions detected in the karyotype and translocations with concomitant deletion at 13q14 in chronic lymphocytic leukemia: Different genetic mechanisms but equivalent poorer clinical outcome

    Genes Chromosomes and Cancer, Vol. 53, Núm. 9, pp. 788-797

2011

  1. Invasive fungal infections in onco-haematology: A spanish perspective

    Revista Espanola de Quimioterapia, Vol. 24, Núm. 3, pp. 168-172

2010

  1. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

    Haematologica, Vol. 95, Núm. 3, pp. 424-431

2008

  1. Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: Long-term outcome of the LPA 99 multicenter study by the PETHEMA Group

    Blood, Vol. 112, Núm. 8, pp. 3130-3134

2004

  1. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: The GEL/TAMO experience

    Annals of Oncology, Vol. 15, Núm. 10, pp. 1504-1509

2003

  1. Autologous stem cell transplantation for primary refractory Hodgkin's disease: Results and clinical variables affecting outcome

    Annals of Oncology, Vol. 14, Núm. 5, pp. 745-751

  2. High-dose therapy in diffuse large cell lymphoma: Results and prognostic factors in 452 patients from the GEL-TAMO Spanish cooperative group

    Annals of Oncology, Vol. 14, Núm. 1, pp. 140-151

  3. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051

  4. t(10;16)(q22;p13) and MORF-CREBBP fusion is a recurrent event in acute myeloid leukemia

    Genes Chromosomes and Cancer, Vol. 36, Núm. 4, pp. 402-405